Table 2 Survival data of eligible studies
Study | Chemo-regimen -Control arm -X arm | TNBC NO. -Control arm -X arm | HR(95%CI) for Survival data(5-year evaluated) X arm vs Control arm | Subgroup analysis in TNBC patients | ||||
|---|---|---|---|---|---|---|---|---|
OS | DFS | RFS | LRRFS | DMFS | ||||
USO 01062 | -4 AC-4 T -4 AC-4 TX | −384 −396 | 0.62 (0.41–0.94) | 0.81 (0.57–1.15) | NS | NS | NS | NS |
GEICAM/2003 | -4EC-4 T -4ET-4X | −71 −95 | NS | 1.19 (0.70–2.04) | NS | NS | NS | All LN positive |
FinXX | -3 T-3CEF -3TX-3CEX | −109 −93 | NS | NS | 0.53 (0.31–0.92) | NS | NS | NS |
CREATE-X | -standard NACT -standard NACT +  6-8X | −147 −139 | 0.52 (0.30–0.90) | 0.58 (0.39–0.87) | NS | NS | NS | NS |
CIBOMA/2004 | -standard CT -standard CT + 8X | −428 −448 | 0.92 (0.66–1.28) | 0.82 (0.63–1.06) | NS | NS | NS | LN status; menopausal status |
CBCSG-010 | -3 T-3CEF -3TX-3CEX | −288 −297 | 0.67 (0.37–1.22) | 0.66 (0.44–0.99) | 0.59 (0.38–0.93) | NS | 0.63 (0.39–1.00) | LN status; menopausal status |
SYSUCC-001 | -standard CT -standard CT + X(1 year) | −213 −221 | 0.75 (0.47–1.19) | 0.64 (0.42–0.95) | NS | 0.72 (0.46–1.13) | 0.60 (0.38–0.92) | LN status; menopausal status |